Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. The JSPR news feed highlights company announcements on clinical data, corporate developments and financing activities that shape the outlook for this mast cell–focused program.
News updates commonly cover clinical trial results and study updates. Jasper has reported data from the BEACON Phase 1b/2a study in CSU, an open-label extension study in chronic urticarias, and the ETESIAN Phase 1b/2a study in allergic asthma. These releases describe endpoints such as Urticaria Activity Score over 7 days (UAS7), hives and itch severity scores, airway hyperresponsiveness, sputum eosinophils, serum tryptase, and safety findings, including observations related to KIT blockade.
The JSPR news stream also includes corporate and strategic announcements, such as leadership changes, corporate reorganizations, and decisions to concentrate resources on briquilimab in mast cell driven diseases. Investors can find information on Jasper’s participation in healthcare and investor conferences, where management discusses briquilimab’s development and provides program updates.
In addition, Jasper issues financing and capital markets news, including details of public offerings of common stock, pre-funded warrants and common warrants, and stated uses of proceeds for advancing briquilimab and supporting general corporate purposes. Together, these news items provide context on clinical progress, strategic focus and funding for Jasper’s lead program. For readers tracking JSPR, this page offers a centralized view of the company’s press releases and related communications.
Jasper Therapeutics (NASDAQ: JSPR) reported its fiscal year 2021 results, highlighting significant advancements in its JSP191 therapy for hematopoietic stem cell transplants. In a Phase 1b study, JSP191 demonstrated a safety record with 100% engraftment and MRD clearance in patients. The company plans to initiate pivotal studies for MDS/AML and a second-line therapeutic study in 2022. Financially, it ended 2021 with $84.7 million in cash, sufficient to fund operations into early 2023. R&D expenses increased to $25.4 million, while net loss decreased slightly to $30.6 million.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the 32nd Annual Oppenheimer Healthcare Investor Conference, taking place virtually from March 15-17, 2022. Ronald Martell, CEO, will present on March 16 at 1:20 PM ET, with a live webcast available for viewing. Jasper is focused on developing innovative hematopoietic cell transplant therapies, including JSP191, a monoclonal antibody aimed at improving transplant safety and efficacy. The company also advances a preclinical mRNA engineered hematopoietic stem cell platform, designed to enhance treatment options for patients with serious conditions.
Jasper Therapeutics announces Ronald Martell as the new CEO, effective March 15, 2022. Martell, with a strong background in biopharmaceuticals, aims to lead the company through its next growth phase. He emphasized the potential of Jasper's JSP191 and mRNA engineered stem cell programs, citing promising Phase 1b clinical data showing 100% engraftment success in patients with MDS/AML. Jasper's programs target safer stem cell transplants to treat various diseases. The company has a solid financial foundation and is focusing on advancing its clinical pipeline.
Jasper Therapeutics announced promising preliminary findings from a Phase 1b study of JSP191 in older patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). All 17 subjects in the trial achieved successful engraftment with neutrophil recovery, and 12 of 15 patients with measurable residual disease cleared their conditions. JSP191 demonstrated a favorable safety profile, with no severe adverse events reported. These results, to be presented at the 2022 TCT meeting, signal potential for JSP191 as a new conditioning agent in hematopoietic stem cell transplants.
Jasper Therapeutics (NASDAQ: JSPR) announced promising data on JSP191, presented at the 2021 American Society of Hematology Annual Meeting. The study showed JSP191 to be well tolerated, with no treatment-related adverse events reported among patients aged 3 months to 38 years. A total of six out of nine patients achieved hematopoietic stem cell (HSC) engraftment and demonstrated clinical improvement. The ongoing study is evaluating the 0.6 mg/kg dose as a potential recommended Phase 2 dose. JSP191 aims to enhance the safety and efficacy of hematopoietic cell transplants for severe combined immunodeficiency (SCID).
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced its Q3 2021 results, marking a significant quarter post-IPO. The company raised $100 million in gross proceeds after merging with Amplitude Healthcare Acquisition Corporation. JSP191 clinical trials are on track, with top-line interim data expected in Q1 2022. The company secured FDA Orphan and Rare Pediatric Disease designations for JSP191. Cash reserves of $100.9 million are projected to fund operations through mid-2023. Despite an increase in R&D expenses to $7.2 million, the net loss narrowed to $3.4 million from $10.8 million in Q3 2020.
Jasper Therapeutics (JSPR) announces a non-exclusive research collaboration with AVROBIO to explore JSP191 as a targeted conditioning agent for patients with Fabry disease and Gaucher disease type 1 undergoing AVROBIO's gene therapies. CEO Bill Lis emphasized the collaboration enhances JSP191's potential in gene therapies. JSP191 is an anti-CD117 monoclonal antibody in clinical development, currently evaluated in over 90 healthy volunteers and patients, with ongoing trials for various hematological conditions.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) will be presenting at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 10, 2021, at 11:40 a.m. Pacific Time. Bill Lis, Executive Chairman and CEO, will lead the presentation, which will be available via a live webcast. Jasper focuses on hematopoietic cell transplant therapies, with two promising programs in development: JSP191, a monoclonal antibody aimed at safer transplants, and a preclinical mRNA engineered hematopoietic stem cell platform. Their innovations aim to expand treatment options for patients with serious medical conditions.